<DOC>
	<DOCNO>NCT01309204</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Brinzolamide/Brimonidine fix combination lower intraocular pressure ( IOP ) relative individual active constituent instill concomitantly ( Brinzolamide+Brimonidine ) patient open-angle glaucoma ocular hypertension .</brief_summary>
	<brief_title>Brinzolamide/Brimonidine Twice Day ( BID ) Fixed Combination ( FC ) v Brinzolamide BID Plus Brimonidine BID Patients With Open Angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description>This study consist 7 visit conduct 2 sequential phase : screening/eligibility phase , include screen visit 2 eligibility visit , treatment phase , include 4 on-therapy visit conduct Week 2 , Week 6 , Month 3 , Month 6 ( early exit ) . Following washout IOP-lowering medication , subject meet inclusion/exclusion criterion eligibility visit IOP measurement within specified range period randomize 1 2 study drug group : Brinz/Brim Brinz+Brim .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diagnosed openangle glaucoma ocular hypertension , opinion Investigator , insufficiently control monotherapy currently multiple IOPlowering medication . Meet qualify IOP entry criterion . Able understand sign inform consent form . Other protocolspecified inclusion criterion may apply . Women childbearing potential pregnant , test positive pregnancy Screening visit , breastfeeding , agreement use adequate birth control method prevent pregnancy throughout study . Severe central visual field loss . Can safely undergo initial washout period discontinue use IOPlowering ocular medication ( ) minimum specified period prior Eligibility Visit 1 . Best correct visual acuity ( BCVA ) score bad 55 ETDRS letter ( 20/80 Snellen equivalent ) . Chronic , recurrent severe inflammatory eye disease . Ocular trauma within precede 6 month . Ocular infection inflammation within precede 3 month . Clinically significant progressive retinal disease . Other ocular pathology . Intraocular surgery within 6 month prior entry . Ocular laser surgery within 3 month prior entry . Any abnormality prevent reliable applanation tonometry . Any condition would make patient , opinion Investigator , unsuitable study . Recent use highdose ( &gt; 1 gram daily ) salicylate therapy . Recent , current , anticipated treatment medication augments adrenergic response , precludes use alphaadrenergic agonist . Other protocolspecified exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>open-angle glaucoma</keyword>
	<keyword>ocular hypertension</keyword>
	<keyword>OAG</keyword>
	<keyword>OHT</keyword>
</DOC>